

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

24 Jun 2026

### comparison of ovulation triggering outcome using these two methods: standard dose of human chorionic gonadotropin and human chorionic gonadotropin In combination with gonadotropin releasing hormone in IVF/ICSI cycles

#### Protocol summary

##### Study aim

comparison of ovulation triggering outcome using these two methods: standard dose of human chorionic gonadotropin and human chorionic gonadotropin In combination with gonadotropin releasing hormone in IVF/ICSI cycles

##### Design

This will be a two arm parallel group design of 100 patients candidate of IVF/ICSI , single blind randomised trial, with a computer-generated randomization list with a block size of 4, with 1:1 allocation.

##### Settings and conduct

Infertile women candidates of IVF/ICSI for different reason, having the study criteria who come to infertility clinic of Alzahra hospital will be entered into the study. First we will take an informed written consent and all part of the study will be explained to the patient. The treatment allocation will be placed in a sealed opaque envelope and picked up consecutively.

##### Participants/Inclusion and exclusion criteria

women who are candidate of IVF/ICSI and have some risk of ovarian hyperstimulation syndrome (OHSS) will be entered in the study. Every body who has diminished ovarian reserve [antral follicular count (AFC) less than 4 or anti-mulerian hormone (AMH) less than 1] will be excluded.

##### Intervention groups

during ovarian stimulation and ultrasound control when there is at least 5 or more follicles above 17 mm in diameter we administer 0.2 mg decapeptide and 2500 unit HcG for triggering ovulation in the study group or 2 ampoules of 5000 unit HcG equivalent to 10,000 units HcG in the control group.

##### Main outcome variables

number and quality of oocytes: number and quality of embryos: fertilization rate: imlantation rate: the rate of

OHSS

#### General information

##### Reason for update

increment of the sample size and change in the dose of the drug in the control and intervention group because of the mistake in typing

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20101227005485N7**  
Registration date: **2019-07-18, 1398/04/27**  
Registration timing: **registered\_while\_recruiting**

Last update: **2022-02-22, 1400/12/03**

Update count: **1**

##### Registration date

2019-07-18, 1398/04/27

##### Registrant information

###### Name

Nazli Navali

###### Name of organization / entity

Tabriz University of Medical Sciences, Faculty of Medecine

###### Country

Iran (Islamic Republic of)

###### Phone

+98 41 1330 2879

###### Email address

navalin@tbzmed.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-06-22, 1398/04/01  
**Expected recruitment end date**  
2019-12-22, 1398/10/01  
**Actual recruitment start date**  
empty  
**Actual recruitment end date**  
empty  
**Trial completion date**  
empty

**Scientific title**  
comparison of ovulation triggering outcome using these two methods: standard dose of human chorionic gonadotropin and human chorionic gonadotropin In combination with gonadotropin releasing hormone in IVF/ICSI cycles

**Public title**  
comparison of standard dose of human chorionic gonadotropin and human chorionic gonadotropin In combination with gonadotropin releasing hormone in IVF/ICSI cycles

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
women who are candidate of IVF/ICSI and have some risk of OHSS will be entered in the study.  
**Exclusion criteria:**  
every body who have diminished ovarian reserve. (AFC<4 or AMH<1)

**Age**  
From **20 years** old to **40 years** old

**Gender**  
Female

**Phase**  
4

**Groups that have been masked**

- Participant
- Care provider
- Outcome assessor
- Data analyser

**Sample size**  
Target sample size: **100**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
A computer-generated randomization list with a block size of 4, with 1:1 allocation will be used to randomize patients. In such a case, one control will be checked for each intervention and with each of the 4 patients enrolled in the study, the two groups are balanced in terms of control and intervention.

**Blinding (investigator's opinion)**  
Single blinded

**Blinding description**  
The treatment allocation will be placed in a sealed, opaque, envelope and picked up consecutively. in the manner that the participant, the outcome evaluator and the analyzer will not be aware of the type of the drug.

**Placebo**

Not used  
**Assignment**  
Parallel  
**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Tabriz University of Medical Sciences

##### Street address

Research Deputy of Tabriz University of Medical Sciences, University of Tabriz, Golgasht street

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5166614711

#### Approval date

2019-05-07, 1398/02/17

#### Ethics committee reference number

IR.TBZMED.REC.1398.129

## Health conditions studied

### 1

#### Description of health condition studied

infertility

#### ICD-10 code

N97

#### ICD-10 code description

Female infertility

## Primary outcomes

### 1

#### Description

number and quality of resulted oocytes

#### Timepoint

the day of oocytes pick up

#### Method of measurement

microscopic evaluation

### 2

#### Description

fertilization rate

#### Timepoint

24 hours after intra-cytoplasmic sperm injection

#### Method of measurement

microscope

### 3

**Description**

implantation rate

**Timepoint**

2 weeks after embryo transfer

**Method of measurement**

Measurement of beta-hCG

### 4

**Description**

number and quality of embryos

**Timepoint**

after 24 hours, day 3 and day 5

**Method of measurement**

microscopic evaluation

## Secondary outcomes

### 1

**Description**

ovarian hyperstimulation syndrome

**Timepoint**

the day of oocyte pick-up and a week later

**Method of measurement**

history, physical examination and laboratory tests

## Intervention groups

### 1

**Description**

Intervention group: 2500 unit human chorionic gonadotropin In combination with 0.2 miligram gonadotropin releasing hormone

**Category**

Treatment - Drugs

### 2

**Description**

Control group: 10000 unit human chorionic gonadotropin for triggering

**Category**

Treatment - Drugs

## Recruitment centers

### 1

**Recruitment center****Name of recruitment center**

Alzahra Hospital

**Full name of responsible person**

Navali Nazli

**Street address**

south Artesh street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138665793

**Phone**

+98 41 3554 1221

**Email**

navalin@tbzmed.ac.ir

**Web page address**

<http://alzahrahosp.tbzmed.ac.ir>

## Sponsors / Funding sources

### 1

**Sponsor****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Dr. Elahe Saheb Olad Madarek

**Street address**

Artesh street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138665793

**Phone**

+98 41 3554 1221

**Email**

navalin@tbzmed.ac.ir

**Web page address**

<http://alzahrahosp.tbzmed.ac.ir>

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tabriz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Nazli Navali

**Position**

infertility fellowship/associate professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Artesh street, Alzahra Hospita, infertility department

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138665793

**Phone**

+98 41 3554 1221

**Email**

navalin@tbzmed.ac.ir

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Nazli Navali

**Position**

associate professor/infertility fellowship

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Infertility department, Alzahra Hospital, Artesh street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138665793

**Phone**

+98 41 3554 1221

**Email**

navalin@tbzmed.ac.ir

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Nazli Navali

**Position**

associate professor/infertility fellowship

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Infertility department, Alzahra Hospital, Artesh street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138665793

**Phone**

+98 41 3554 1221

**Email**

navalin@tbzmed.ac.ir

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

only a part of data could be shared

**When the data will become available and for how long**

2 years after publishing the results, the data could be attained.

**To whom data/document is available**

data will be given for every academic person who is interested in this field.

**Under which criteria data/document could be used**

for utilization in researches like in metha-analyses

**From where data/document is obtainable**

the applicants can mail there request to the person responsible for scientific inquiries.

**What processes are involved for a request to access data/document**

after application, data will be sent in two weeks.

**Comments**